Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Взаимодействие антигипертензивных лекарственных средств и розувастатина: фокус на безопасность, эффективность и перспективы - Журнал Системные Гипертензии Том 14, №3
Взаимодействие антигипертензивных лекарственных средств и розувастатина: фокус на безопасность, эффективность и перспективы
Лучинина Е.В., Компаниец О.Г., Кижватова Н.В. Взаимодействие антигипертензивных лекарственных средств и розувастатина: фокус на безопасность, эффективность и перспективы. Системные гипертензии. 2017; 14 (3): 79–83. DOI: 10.26442/2075-082X_14.3.79-83
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Артериальная гипертензия и дислипидемия являются часто встречающейся коморбидной патологией, регистрирующейся у 40–70% пациентов. Статины показаны как для первичной, так и для вторичной профилактики сердечно-сосудистых заболеваний и осложнений. Мы попытались проанализировать некоторые данные о статинах и их взаимодействии с антигипертензивными препаратами. Розувастатин является препаратом, обеспечивающим интенсивное снижение липопротеидов низкой плотности, не требует коррекции дозы при применении совместно с антигипертензивными препаратами. Отсутствие ингибиции и активации розувастатином цитохромов Р450 обеспечивает низкий риск негативных взаимодействий в клинических ситуациях вынужденной полипрагмазии. Практикующим врачам необходимо учитывать вероятность побочных реакций при сочетании статинов с рядом препаратов из других клинико-фармакологических групп.
Ключевые слова: артериальная гипертензия, дислипидемии, розувастатин, антигипертензивные препараты.
Key words: аrterial hypertension, dyslipidemia, rosuvastatin, antihypertensive drugs.
Ключевые слова: артериальная гипертензия, дислипидемии, розувастатин, антигипертензивные препараты.
________________________________________________
Key words: аrterial hypertension, dyslipidemia, rosuvastatin, antihypertensive drugs.
Полный текст
Список литературы
1. Mancia G, Fagard R, Narkiewicz K et al. ESH-ESC Task Force on the Management of Arterial Hypertension. 2013 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. Eur Heart J. DOI: 10.1093/eurheartj/eht151
2. Чазова И.Е., Ощепкова Е.В., Жернакова Ю.В. Клинические рекомендации. Диагностика и лечение артериальной гипертонии. Кардиол. вестн. 2015; 1: 5–30. / Chazova I.E., Oshchepkova E.V., Zhernakova Iu.V. Klinicheskie rekomendatsii. Diagnostika i lechenie arterial'noi gipertonii. Kardiol. vestn. 2015; 1: 5–30. [in Russian]
3. Catapano A et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J 2016; 37 (39): 2999–3058.
4. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации, VI пересмотр. М., 2017. http://www.scardio.ru/content/Guidelines/rek_lipid_2012.pdf / Diagnostika i korrektsiia narushenii lipidnogo obmena s tsel'iu profilaktiki i lecheniia ateroskleroza. Rossiiskie rekomendatsii, VI peresmotr. M., 2017. http://www.scardio.ru/content/Guidelines/rek_lipid_2012.pdf [in Russian]
5. Piepoli M et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2016; 37 (29): 2315–81.
6. Waters DD, Guyton JR, Herrington DM et al. Treating to New Targets (TNT) study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit? Am J Cardiol 2004; 93 (2): 154–8.
7. Karlson BW, Palmer MK, Nicholls S et al. To what extent do high-intensity statins reduce low-density lipoprotein cholesterol in each of the four statin benefit groups identified by the 2013 American College of Cardiology/American Heart Association guidelines. A VOYAGER meta-analysis. Atherosclerosis. 2015; 241 (2): 450–4.
8. LaRosa JC, Grundy SM, Waters DD et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352 (14): 1425–35.
9. Jones PH, Davidson MH, Stein EA et al. STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol 2003; 92: 152–60.
10. Leiter LA, Rosenson RS, Stein E et al; POLARIS study investigators. Efficacy and safety of rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: results of the POLARIS study. Atherosclerosis 2007; 194 (2): e154–e164.
11. Nissen SE, Nicholls SJ, Sipahi I et al. Effect of high-intensive statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006; 295: 1556–65.
12. Государственный реестр лекарственных средств. http://grls.rosminzdrav.ru / Gosudarstvennyi reestr lekarstvennykh sredstv. http://grls.rosminzdrav.ru [in Russian]
13. Christie M, Ballantynea RC, Hoogeveena JL et al. Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg pluse zetimibe 10 mg vs. simvastatin 40 or 80 mg pluse zetimibe 10 mg in high-risk patients: Results of the GRAVITY randomized study. Atherosclerosis 2014; 232: 86–93. https://doi.org/10.1016/j.atherosclerosis.2013.10.022
14. Смоленская О.Г., Макарова, В.Л., Зенин Д.М., Суслов С.А. Значение артериальной гипертонии и нарушений углеводного обмена в развитии коронарного атеросклероза. Системные гипертензии. 2008; 5 (1). / Smolenskaia O.G., Makarova, V.L., Zenin D.M., Suslov S.A. Znachenie arterial'noi gipertonii i narushenii uglevodnogo obmena v razvitii koronarnogo ateroskleroza. Systemic Hypertension. 2008; 5 (1). [in Russian]
15. Синькова Г.М. Факторы общего сердечно-сосудистого риска у больных артериальной гипертензией в сельских и отдаленных районах Иркутской области. Сиб. мед. журн. 2009; 91 (8): 98–100. / Sin'kova G.M. Faktory obshchego serdechno-sosudistogo riska u bol'nykh arterial'noi gipertenziei v sel'skikh i otdalennykh raionakh Irkutskoi oblasti. Sib. med. zhurn. 2009; 91 (8): 98–100. [in Russian]
16. Khokhlov AL, Javorskij AN, Ignat'ev VS et al. Safety culture of drug therapy. Yaroslavl, 2011.
17. Schröder J, Goltz L, Knoth H. Simvastatin and Amlodipin – a clinically relevant drug-interaction? Dtsch Med Wochenschr 2016; 141 (21): 1575–7.
18. Pietsch U, Müller-Höcker C, Filipovic M. Brown urine: Myoglobin-induced renal failure after concomitant administration of simvastatin and amiodarone. Anaesthesist 2016; 65 (5): 366–8. DOI: 10.1007/s00101-016-0171-6
19. Shaik AN, Bohnert T, Williams DA et al. Mechanism of Drug-Drug Interactions Between Warfarin and Statins. J Pharm Sci 2016; 105 (6): 1976–86. DOI: 10.1016/j.xphs.2016.03.011
20. Leoncini M, Toso A, Maioli M, Bellandi F. Statin and clopidogrel pharmacological interaction. G Ital Cardiol (Rome) 2013; 14 (9): 574–84. DOI: 10.1714/1311.14483
21. Panes O, González C, Hidalgo P et al. Platelet tissue factor activity and membrane cholesterol are increased in hypercholesterolemia and normalized by rosuvastatin, but not by atorvastatin. Atherosclerosis 2017; 257: 164–71. DOI: 10.1016/j.atherosclerosis.2016.12.019
22. Zhaohuan Li, Lin Wang, Xiaobo Hu et al. Effect of rosuvastatin on atherosclerotic plaque stability. Atherosclerosis 2016; 248: 27–35. https://doi.org/10.1016/j.atherosclerosis.2016.02.028
23. Andora M, Suciub M, Cristescub C et al. Short-term rosuvastatin therapy influence on restored endothelial function in hypertensive patients. Atherosclerosis 2014; 235 (2): e92. https://doi.org/10.1016/j.atherosclerosis.2014.05.243
24. Jamol Uzokov, Anis Alyavi, Baxrom Alyavi. Volume Influence of combination therapy of rosuvastatin and telmisartan on vascular and metabolic profile in hypercholesterolemic patients with metabolic syndrome Author links open overlay panel. Atherosclerosis 2017; 263: e241. https://doi.org/10.1016/j.atherosclerosis.2017.06.782
25. Kim SH, Lee HL, Lim WH et al. Efficacy and safety of fixed-dose combination of olmesartan medoxomil and rosuvastatin in Korean patients with hypertension and dyslipidemia. Atherosclerosis 2016; 252: e57.
26. Chen J1, Li D, Schaefer R, Mehta JL. Cross-talk between dyslipidemia and renin-angiotensin system and the role of LOX-1 and MAPK in atherogenesis: Studies with the combined use of rosuvastatin and candesartan. Atherosclerosis 2006; 184 (2). https://doi.org/10.1016/j.atherosclerosis.2005.04.016
27. Jandeleit-Dahm K, Rajaram Y, Giunti S et al. Th-P16:286 Effects of rosuvastatin combined with candesartan on oxidative stress and inflammatory parameters in diabetes accelerated atherosclerosis. Atherosclerosis Suppl 2006; 7 (3): 556. https://doi.org/10.1016/S1567-5688(06)82244-0
2. Chazova I.E., Oshchepkova E.V., Zhernakova Iu.V. Klinicheskie rekomendatsii. Diagnostika i lechenie arterial'noi gipertonii. Kardiol. vestn. 2015; 1: 5–30. [in Russian]
3. Catapano A et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J 2016; 37 (39): 2999–3058.
4. Diagnostika i korrektsiia narushenii lipidnogo obmena s tsel'iu profilaktiki i lecheniia ateroskleroza. Rossiiskie rekomendatsii, VI peresmotr. M., 2017. http://www.scardio.ru/content/Guidelines/rek_lipid_2012.pdf [in Russian]
5. Piepoli M et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2016; 37 (29): 2315–81.
6. Waters DD, Guyton JR, Herrington DM et al. Treating to New Targets (TNT) study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit? Am J Cardiol 2004; 93 (2): 154–8.
7. Karlson BW, Palmer MK, Nicholls S et al. To what extent do high-intensity statins reduce low-density lipoprotein cholesterol in each of the four statin benefit groups identified by the 2013 American College of Cardiology/American Heart Association guidelines. A VOYAGER meta-analysis. Atherosclerosis. 2015; 241 (2): 450–4.
8. LaRosa JC, Grundy SM, Waters DD et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352 (14): 1425–35.
9. Jones PH, Davidson MH, Stein EA et al. STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol 2003; 92: 152–60.
10. Leiter LA, Rosenson RS, Stein E et al; POLARIS study investigators. Efficacy and safety of rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: results of the POLARIS study. Atherosclerosis 2007; 194 (2): e154–e164.
11. Nissen SE, Nicholls SJ, Sipahi I et al. Effect of high-intensive statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006; 295: 1556–65.
12. Gosudarstvennyi reestr lekarstvennykh sredstv. http://grls.rosminzdrav.ru [in Russian]
13. Christie M, Ballantynea RC, Hoogeveena JL et al. Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg pluse zetimibe 10 mg vs. simvastatin 40 or 80 mg pluse zetimibe 10 mg in high-risk patients: Results of the GRAVITY randomized study. Atherosclerosis 2014; 232: 86–93. https://doi.org/10.1016/j.atherosclerosis.2013.10.022
14. Smolenskaia O.G., Makarova, V.L., Zenin D.M., Suslov S.A. Znachenie arterial'noi gipertonii i narushenii uglevodnogo obmena v razvitii koronarnogo ateroskleroza. Systemic Hypertension. 2008; 5 (1). [in Russian]
15. Sin'kova G.M. Faktory obshchego serdechno-sosudistogo riska u bol'nykh arterial'noi gipertenziei v sel'skikh i otdalennykh raionakh Irkutskoi oblasti. Sib. med. zhurn. 2009; 91 (8): 98–100. [in Russian]
16. Khokhlov AL, Javorskij AN, Ignat'ev VS et al. Safety culture of drug therapy. Yaroslavl, 2011.
17. Schröder J, Goltz L, Knoth H. Simvastatin and Amlodipin – a clinically relevant drug-interaction? Dtsch Med Wochenschr 2016; 141 (21): 1575–7.
18. Pietsch U, Müller-Höcker C, Filipovic M. Brown urine: Myoglobin-induced renal failure after concomitant administration of simvastatin and amiodarone. Anaesthesist 2016; 65 (5): 366–8. DOI: 10.1007/s00101-016-0171-6
19. Shaik AN, Bohnert T, Williams DA et al. Mechanism of Drug-Drug Interactions Between Warfarin and Statins. J Pharm Sci 2016; 105 (6): 1976–86. DOI: 10.1016/j.xphs.2016.03.011
20. Leoncini M, Toso A, Maioli M, Bellandi F. Statin and clopidogrel pharmacological interaction. G Ital Cardiol (Rome) 2013; 14 (9): 574–84. DOI: 10.1714/1311.14483
21. Panes O, González C, Hidalgo P et al. Platelet tissue factor activity and membrane cholesterol are increased in hypercholesterolemia and normalized by rosuvastatin, but not by atorvastatin. Atherosclerosis 2017; 257: 164–71. DOI: 10.1016/j.atherosclerosis.2016.12.019
22. Zhaohuan Li, Lin Wang, Xiaobo Hu et al. Effect of rosuvastatin on atherosclerotic plaque stability. Atherosclerosis 2016; 248: 27–35. https://doi.org/10.1016/j.atherosclerosis.2016.02.028
23. Andora M, Suciub M, Cristescub C et al. Short-term rosuvastatin therapy influence on restored endothelial function in hypertensive patients. Atherosclerosis 2014; 235 (2): e92. https://doi.org/10.1016/j.atherosclerosis.2014.05.243
24. Jamol Uzokov, Anis Alyavi, Baxrom Alyavi. Volume Influence of combination therapy of rosuvastatin and telmisartan on vascular and metabolic profile in hypercholesterolemic patients with metabolic syndrome Author links open overlay panel. Atherosclerosis 2017; 263: e241. https://doi.org/10.1016/j.atherosclerosis.2017.06.782
25. Kim SH, Lee HL, Lim WH et al. Efficacy and safety of fixed-dose combination of olmesartan medoxomil and rosuvastatin in Korean patients with hypertension and dyslipidemia. Atherosclerosis 2016; 252: e57.
26. Chen J1, Li D, Schaefer R, Mehta JL. Cross-talk between dyslipidemia and renin-angiotensin system and the role of LOX-1 and MAPK in atherogenesis: Studies with the combined use of rosuvastatin and candesartan. Atherosclerosis 2006; 184 (2). https://doi.org/10.1016/j.atherosclerosis.2005.04.016
27. Jandeleit-Dahm K, Rajaram Y, Giunti S et al. Th-P16:286 Effects of rosuvastatin combined with candesartan on oxidative stress and inflammatory parameters in diabetes accelerated atherosclerosis. Atherosclerosis Suppl 2006; 7 (3): 556. https://doi.org/10.1016/S1567-5688(06)82244-0
2. Чазова И.Е., Ощепкова Е.В., Жернакова Ю.В. Клинические рекомендации. Диагностика и лечение артериальной гипертонии. Кардиол. вестн. 2015; 1: 5–30. / Chazova I.E., Oshchepkova E.V., Zhernakova Iu.V. Klinicheskie rekomendatsii. Diagnostika i lechenie arterial'noi gipertonii. Kardiol. vestn. 2015; 1: 5–30. [in Russian]
3. Catapano A et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J 2016; 37 (39): 2999–3058.
4. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации, VI пересмотр. М., 2017. http://www.scardio.ru/content/Guidelines/rek_lipid_2012.pdf / Diagnostika i korrektsiia narushenii lipidnogo obmena s tsel'iu profilaktiki i lecheniia ateroskleroza. Rossiiskie rekomendatsii, VI peresmotr. M., 2017. http://www.scardio.ru/content/Guidelines/rek_lipid_2012.pdf [in Russian]
5. Piepoli M et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2016; 37 (29): 2315–81.
6. Waters DD, Guyton JR, Herrington DM et al. Treating to New Targets (TNT) study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit? Am J Cardiol 2004; 93 (2): 154–8.
7. Karlson BW, Palmer MK, Nicholls S et al. To what extent do high-intensity statins reduce low-density lipoprotein cholesterol in each of the four statin benefit groups identified by the 2013 American College of Cardiology/American Heart Association guidelines. A VOYAGER meta-analysis. Atherosclerosis. 2015; 241 (2): 450–4.
8. LaRosa JC, Grundy SM, Waters DD et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352 (14): 1425–35.
9. Jones PH, Davidson MH, Stein EA et al. STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol 2003; 92: 152–60.
10. Leiter LA, Rosenson RS, Stein E et al; POLARIS study investigators. Efficacy and safety of rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: results of the POLARIS study. Atherosclerosis 2007; 194 (2): e154–e164.
11. Nissen SE, Nicholls SJ, Sipahi I et al. Effect of high-intensive statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006; 295: 1556–65.
12. Государственный реестр лекарственных средств. http://grls.rosminzdrav.ru / Gosudarstvennyi reestr lekarstvennykh sredstv. http://grls.rosminzdrav.ru [in Russian]
13. Christie M, Ballantynea RC, Hoogeveena JL et al. Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg pluse zetimibe 10 mg vs. simvastatin 40 or 80 mg pluse zetimibe 10 mg in high-risk patients: Results of the GRAVITY randomized study. Atherosclerosis 2014; 232: 86–93. https://doi.org/10.1016/j.atherosclerosis.2013.10.022
14. Смоленская О.Г., Макарова, В.Л., Зенин Д.М., Суслов С.А. Значение артериальной гипертонии и нарушений углеводного обмена в развитии коронарного атеросклероза. Системные гипертензии. 2008; 5 (1). / Smolenskaia O.G., Makarova, V.L., Zenin D.M., Suslov S.A. Znachenie arterial'noi gipertonii i narushenii uglevodnogo obmena v razvitii koronarnogo ateroskleroza. Systemic Hypertension. 2008; 5 (1). [in Russian]
15. Синькова Г.М. Факторы общего сердечно-сосудистого риска у больных артериальной гипертензией в сельских и отдаленных районах Иркутской области. Сиб. мед. журн. 2009; 91 (8): 98–100. / Sin'kova G.M. Faktory obshchego serdechno-sosudistogo riska u bol'nykh arterial'noi gipertenziei v sel'skikh i otdalennykh raionakh Irkutskoi oblasti. Sib. med. zhurn. 2009; 91 (8): 98–100. [in Russian]
16. Khokhlov AL, Javorskij AN, Ignat'ev VS et al. Safety culture of drug therapy. Yaroslavl, 2011.
17. Schröder J, Goltz L, Knoth H. Simvastatin and Amlodipin – a clinically relevant drug-interaction? Dtsch Med Wochenschr 2016; 141 (21): 1575–7.
18. Pietsch U, Müller-Höcker C, Filipovic M. Brown urine: Myoglobin-induced renal failure after concomitant administration of simvastatin and amiodarone. Anaesthesist 2016; 65 (5): 366–8. DOI: 10.1007/s00101-016-0171-6
19. Shaik AN, Bohnert T, Williams DA et al. Mechanism of Drug-Drug Interactions Between Warfarin and Statins. J Pharm Sci 2016; 105 (6): 1976–86. DOI: 10.1016/j.xphs.2016.03.011
20. Leoncini M, Toso A, Maioli M, Bellandi F. Statin and clopidogrel pharmacological interaction. G Ital Cardiol (Rome) 2013; 14 (9): 574–84. DOI: 10.1714/1311.14483
21. Panes O, González C, Hidalgo P et al. Platelet tissue factor activity and membrane cholesterol are increased in hypercholesterolemia and normalized by rosuvastatin, but not by atorvastatin. Atherosclerosis 2017; 257: 164–71. DOI: 10.1016/j.atherosclerosis.2016.12.019
22. Zhaohuan Li, Lin Wang, Xiaobo Hu et al. Effect of rosuvastatin on atherosclerotic plaque stability. Atherosclerosis 2016; 248: 27–35. https://doi.org/10.1016/j.atherosclerosis.2016.02.028
23. Andora M, Suciub M, Cristescub C et al. Short-term rosuvastatin therapy influence on restored endothelial function in hypertensive patients. Atherosclerosis 2014; 235 (2): e92. https://doi.org/10.1016/j.atherosclerosis.2014.05.243
24. Jamol Uzokov, Anis Alyavi, Baxrom Alyavi. Volume Influence of combination therapy of rosuvastatin and telmisartan on vascular and metabolic profile in hypercholesterolemic patients with metabolic syndrome Author links open overlay panel. Atherosclerosis 2017; 263: e241. https://doi.org/10.1016/j.atherosclerosis.2017.06.782
25. Kim SH, Lee HL, Lim WH et al. Efficacy and safety of fixed-dose combination of olmesartan medoxomil and rosuvastatin in Korean patients with hypertension and dyslipidemia. Atherosclerosis 2016; 252: e57.
26. Chen J1, Li D, Schaefer R, Mehta JL. Cross-talk between dyslipidemia and renin-angiotensin system and the role of LOX-1 and MAPK in atherogenesis: Studies with the combined use of rosuvastatin and candesartan. Atherosclerosis 2006; 184 (2). https://doi.org/10.1016/j.atherosclerosis.2005.04.016
27. Jandeleit-Dahm K, Rajaram Y, Giunti S et al. Th-P16:286 Effects of rosuvastatin combined with candesartan on oxidative stress and inflammatory parameters in diabetes accelerated atherosclerosis. Atherosclerosis Suppl 2006; 7 (3): 556. https://doi.org/10.1016/S1567-5688(06)82244-0
________________________________________________
2. Chazova I.E., Oshchepkova E.V., Zhernakova Iu.V. Klinicheskie rekomendatsii. Diagnostika i lechenie arterial'noi gipertonii. Kardiol. vestn. 2015; 1: 5–30. [in Russian]
3. Catapano A et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J 2016; 37 (39): 2999–3058.
4. Diagnostika i korrektsiia narushenii lipidnogo obmena s tsel'iu profilaktiki i lecheniia ateroskleroza. Rossiiskie rekomendatsii, VI peresmotr. M., 2017. http://www.scardio.ru/content/Guidelines/rek_lipid_2012.pdf [in Russian]
5. Piepoli M et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2016; 37 (29): 2315–81.
6. Waters DD, Guyton JR, Herrington DM et al. Treating to New Targets (TNT) study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit? Am J Cardiol 2004; 93 (2): 154–8.
7. Karlson BW, Palmer MK, Nicholls S et al. To what extent do high-intensity statins reduce low-density lipoprotein cholesterol in each of the four statin benefit groups identified by the 2013 American College of Cardiology/American Heart Association guidelines. A VOYAGER meta-analysis. Atherosclerosis. 2015; 241 (2): 450–4.
8. LaRosa JC, Grundy SM, Waters DD et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352 (14): 1425–35.
9. Jones PH, Davidson MH, Stein EA et al. STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol 2003; 92: 152–60.
10. Leiter LA, Rosenson RS, Stein E et al; POLARIS study investigators. Efficacy and safety of rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: results of the POLARIS study. Atherosclerosis 2007; 194 (2): e154–e164.
11. Nissen SE, Nicholls SJ, Sipahi I et al. Effect of high-intensive statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006; 295: 1556–65.
12. Gosudarstvennyi reestr lekarstvennykh sredstv. http://grls.rosminzdrav.ru [in Russian]
13. Christie M, Ballantynea RC, Hoogeveena JL et al. Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg pluse zetimibe 10 mg vs. simvastatin 40 or 80 mg pluse zetimibe 10 mg in high-risk patients: Results of the GRAVITY randomized study. Atherosclerosis 2014; 232: 86–93. https://doi.org/10.1016/j.atherosclerosis.2013.10.022
14. Smolenskaia O.G., Makarova, V.L., Zenin D.M., Suslov S.A. Znachenie arterial'noi gipertonii i narushenii uglevodnogo obmena v razvitii koronarnogo ateroskleroza. Systemic Hypertension. 2008; 5 (1). [in Russian]
15. Sin'kova G.M. Faktory obshchego serdechno-sosudistogo riska u bol'nykh arterial'noi gipertenziei v sel'skikh i otdalennykh raionakh Irkutskoi oblasti. Sib. med. zhurn. 2009; 91 (8): 98–100. [in Russian]
16. Khokhlov AL, Javorskij AN, Ignat'ev VS et al. Safety culture of drug therapy. Yaroslavl, 2011.
17. Schröder J, Goltz L, Knoth H. Simvastatin and Amlodipin – a clinically relevant drug-interaction? Dtsch Med Wochenschr 2016; 141 (21): 1575–7.
18. Pietsch U, Müller-Höcker C, Filipovic M. Brown urine: Myoglobin-induced renal failure after concomitant administration of simvastatin and amiodarone. Anaesthesist 2016; 65 (5): 366–8. DOI: 10.1007/s00101-016-0171-6
19. Shaik AN, Bohnert T, Williams DA et al. Mechanism of Drug-Drug Interactions Between Warfarin and Statins. J Pharm Sci 2016; 105 (6): 1976–86. DOI: 10.1016/j.xphs.2016.03.011
20. Leoncini M, Toso A, Maioli M, Bellandi F. Statin and clopidogrel pharmacological interaction. G Ital Cardiol (Rome) 2013; 14 (9): 574–84. DOI: 10.1714/1311.14483
21. Panes O, González C, Hidalgo P et al. Platelet tissue factor activity and membrane cholesterol are increased in hypercholesterolemia and normalized by rosuvastatin, but not by atorvastatin. Atherosclerosis 2017; 257: 164–71. DOI: 10.1016/j.atherosclerosis.2016.12.019
22. Zhaohuan Li, Lin Wang, Xiaobo Hu et al. Effect of rosuvastatin on atherosclerotic plaque stability. Atherosclerosis 2016; 248: 27–35. https://doi.org/10.1016/j.atherosclerosis.2016.02.028
23. Andora M, Suciub M, Cristescub C et al. Short-term rosuvastatin therapy influence on restored endothelial function in hypertensive patients. Atherosclerosis 2014; 235 (2): e92. https://doi.org/10.1016/j.atherosclerosis.2014.05.243
24. Jamol Uzokov, Anis Alyavi, Baxrom Alyavi. Volume Influence of combination therapy of rosuvastatin and telmisartan on vascular and metabolic profile in hypercholesterolemic patients with metabolic syndrome Author links open overlay panel. Atherosclerosis 2017; 263: e241. https://doi.org/10.1016/j.atherosclerosis.2017.06.782
25. Kim SH, Lee HL, Lim WH et al. Efficacy and safety of fixed-dose combination of olmesartan medoxomil and rosuvastatin in Korean patients with hypertension and dyslipidemia. Atherosclerosis 2016; 252: e57.
26. Chen J1, Li D, Schaefer R, Mehta JL. Cross-talk between dyslipidemia and renin-angiotensin system and the role of LOX-1 and MAPK in atherogenesis: Studies with the combined use of rosuvastatin and candesartan. Atherosclerosis 2006; 184 (2). https://doi.org/10.1016/j.atherosclerosis.2005.04.016
27. Jandeleit-Dahm K, Rajaram Y, Giunti S et al. Th-P16:286 Effects of rosuvastatin combined with candesartan on oxidative stress and inflammatory parameters in diabetes accelerated atherosclerosis. Atherosclerosis Suppl 2006; 7 (3): 556. https://doi.org/10.1016/S1567-5688(06)82244-0
Авторы
Е.В.Лучинина1, О.Г.Компаниец*2, Н.В.Кижватова2
1 ФГБОУ ВО «Саратовский государственный медицинский университет им. В.И.Разумовского» Минздрава России. 410012, Россия, Саратов, ул. Большая Казачья, д. 112;
2 ФГБОУ ВО «Кубанский государственный медицинский университет» Минздрава России. 350063, Россия, Краснодар, ул. Седина, д. 4;
*Olga-Kompaniets1@yandex.ru
1 V.I.Razumovsky Saratov State Medical University of the Ministry of Health of the Russian Federation. 410012, Russian Federation, Saratov, ul. Bol'shaia Kazach'ia, d. 112;
2 Kuban State Medical University of the Ministry of Health of the Russian Federation. 350063, Russian Federation, Krasnodar, ul. Sedina, d. 4
*Olga-Kompaniets1@yandex.ru
1 ФГБОУ ВО «Саратовский государственный медицинский университет им. В.И.Разумовского» Минздрава России. 410012, Россия, Саратов, ул. Большая Казачья, д. 112;
2 ФГБОУ ВО «Кубанский государственный медицинский университет» Минздрава России. 350063, Россия, Краснодар, ул. Седина, д. 4;
*Olga-Kompaniets1@yandex.ru
________________________________________________
1 V.I.Razumovsky Saratov State Medical University of the Ministry of Health of the Russian Federation. 410012, Russian Federation, Saratov, ul. Bol'shaia Kazach'ia, d. 112;
2 Kuban State Medical University of the Ministry of Health of the Russian Federation. 350063, Russian Federation, Krasnodar, ul. Sedina, d. 4
*Olga-Kompaniets1@yandex.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.